The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019

15.—(1) Schedule 2 is amended as follows. U.K.

(2) In the Schedule heading, for “fee” substitute “ fees and standalone MRL application fees ”.

(3) After the Schedule heading insert the paragraph heading “ Fees for import tolerances ”.

(4) The existing content of the Schedule (after the Schedule heading) becomes paragraph 1.

(5) In that paragraph—

[F1 (a) in the first sentence, for the words from the start to “product-related applications” substitute “Fees chargeable by a Great Britain competent authority for import tolerances”;]

(b) in the table, before item 1 insert—

“A1	Preliminary consideration of an application to determine whether the application can proceed further	229
A2	Co-ordination of applications	1,872”

(c) in the notes following the table—

(i) for note (1) substitute—

“(1) This category is mainly for active substances not currently approved in respect of the part of [F2 Great Britain] to which the application relates. In certain cases it may also include active substances still being reviewed if toxicological endpoints have not yet been agreed and accepted in respect of that part of [F2 Great Britain].”;

(ii) in note (2)—

(aa) for “plant protection products” substitute “ active substances ”;

(bb) for “at a European level” substitute “ and accepted in respect of the part of [F3 Great Britain] to which the application relates ”;

(iii) in note (3)—

(aa) for “plant protection products” substitute “ active substances ”;

(bb) for “at European level” substitute “ and accepted in respect of the part of [F4 Great Britain] to which the application relates ”;

(iv) after note (3) insert—

“Fees for multiple import tolerances for the same active substance are calculated on a modular basis with a charge applied for each crop.”

(6) After that paragraph insert—

“Fees for standalone MRL applications

2.   Fees [F5 chargeable by a Great Britain competent authority] for standalone MRL applications are in accordance with the following table.

Item	Category	Fee (£)
1	Preliminary consideration of an application to determine whether the application can proceed further	229
2	Co-ordination of applications	1,872
3	Full human health description(1)	16,224
4	Metabolism and residues evaluation(2)	6,760
5	Residues evaluation(3)	2,028

Notes

(1) This category is mainly for active substances not currently approved in respect of the part of [F6 Great Britain] to which the application relates. In certain cases it may also include active substances still being reviewed if toxicological endpoints have not yet been agreed and accepted in respect of that part of [F6 Great Britain].

(2) This category is for active substances where toxicological endpoints have already been agreed and accepted in respect of the part of [F6 Great Britain] to which the application relates but the residue definition has only been established for crop groups unrelated to the intended use.

(3) This category is for active substances where relevant toxicological endpoints and residue definition have already been agreed and accepted in respect of the part of [F6 Great Britain] to which the application relates.

Fees for multiple standalone applications for the same active substance are calculated on a modular basis with a charge applied for each crop or combination of maximum residue levels.”

Textual Amendments

F1 Sch. 1 para. 15(5)(a) substituted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(2)(a)

F2 Words in Sch. 1 para. 15(5)(c)(i) substituted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(2)(b)(i)

F3 Words in Sch. 1 para. 15(5)(c)(ii)(bb) substituted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(2)(b)(ii)

F4 Words in Sch. 1 para. 15(5)(c)(iii)(bb) substituted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(2)(b)(ii)

F5 Words in Sch. 1 para. 15(6) inserted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(3)(a)

F6 Words in Sch. 1 para. 15(6) substituted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 11(3)(b)

Commencement Information

I1 Sch. 1 para. 15 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1(2)